Claims

1. A compound of formula (I)

$$(R^{1})_{n}$$
 $(R^{2})_{m}$
 $N - L^{\frac{1}{2}}N - L^{\frac{2}{2}}R^{5}$
 R^{3}
 R^{4}

wherein

15

 R^1 represents a $C_{1.4}$ alkoxy group optionally substituted by one or more fluoro or a $C_{1.4}$ alkyl group optionally substituted by one or more fluoro;

n represents 0 or 1;

 R^2 represents a C_{1-4} alkyl group optionally substituted by one or more fluoro or a C_{1-4}

4alkoxy group optionally substituted by one or more fluoro;

m represents 0 or 1;

R³ represents H or a C₁₋₄alkyl group;

L¹ represents an alkylene chain (CH₂)_r in which r represents 2 or 3 or L¹ represents a cyclohexyl group wherein the two nitrogens bearing R³ and R⁴, respectively, are linked to the cyclohexyl group either via the 1,3 or the 1,4 positions of the cyclohexyl group or L¹ represents a cyclopentyl group wherein the two nitrogens bearing R³ and R⁴, respectively, are linked to the cyclopentyl group via the 1,3 position of the cyclopentyl group and additionally when R⁵ represents 9, 10-methanoanthracen-9(10H)-yl the group -L¹-N(R⁴)-together represents a piperidyl ring which is linked to L² through the piperidinyl nitrogen and to N-R³ via the 4 position of the piperidyl ring with the proviso that when R⁵ represents 9, 10-methanoanthracen-9(10H)-yl then r is only 2;

 R^4 represents H or a $C_{1,4}$ alkyl group optionally substituted by one or more of the following: an aryl group or a heteroaryl group;

L² represents a bond or an alkylene chain (CH₂), in which s represents 1, 2 or 3 wherein the alkylene chain is optionally substituted by one or more of the following: a C₁₋₄alkyl group, phenyl or heteroaryl;

R⁵ represents aryl, a heterocyclic group or a C₃₋₈cycloalkyl group which is optionally fused to a phenyl or to a heteroaryl group;

as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts, thereof;

with a first proviso that when n is 0, and m is 1 and R^2 is methyl located at the 4-position of the quinoline ring, and R^3 is H and R^4 is H and L^1 is $(CH_2)_2$ or $(CH_2)_3$ or 1,4-cyclohexyl, and L^2 is a bond then R^5 is not 4-methylquinolin-2-yl;

and with a second proviso that when n is 0, and m is 0 or 1 and R^2 is a $C_{1.3}$ alkoxy group located at the 4-position of the quinoline ring, and R^3 is H or a $C_{1.3}$ alkyl group and R^4 is H or a $C_{1.3}$ alkyl group and L^1 is $(CH_2)_3$ and L^2 is methylene optionally substituted by one or more $C_{1.3}$ alkyl groups or phenyl then R^5 is not phenyl, thienyl or indolyl optionally substituted by one, two or three $C_{1.4}$ alkyl groups or halo.

- 2. A compound as claimed in claim1 in which R¹ represents a C₁₋₄alkoxy group.
- 3. A compound as claimed in claim1 or claim 2 in which R² represents a C_{1.4}alkyl group.
- A compound as claimed in any previous claim in which L¹ represents trimethylene,
 1,3-cyclohexyl or 1,4-cyclohexyl or when R⁵ represents 9, 10-methanoanthracen-9(10H) yl L¹ additionally represents ethylene.
 - 5. A compound as claimed in any previous claim in which L¹ represents trimethylene.
 - 6. A compound as claimed in any previous claim in which L¹ represents 1,3-cyclohexyl.
 - 7. A compound as claimed in any previous claim in which L¹ represents 1,4-cyclohexyl.
 - 8. A compound as claimed in any previous claim in which L¹ represents 1,3-cyclopentyl.
- 20 9. A compound as claimed in any previous claim in which R³ represents H.
 - 10. A compound as claimed in any previous claim in which L² represents methylene.
 - 11. A compound as claimed in any previous claim in which R⁴ represents H.
 - 12. A compound as claimed in any previous claim in which R⁵ represents phenyl, 2-naphthyl or 9, 10-methanoanthracen-9(10H)-yl, each of which is optionally substituted by one or more of the following: methyl, chloro, dimethylamino or phenyl.
 - 13. A compound as claimed in any previous claim in which R⁵ represents 4, 5, 6, 7-tetrahydrothianaphth-4-yl, benzo[b]thien-3-yl, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, benzofuranyl, pyridyl, 1H-pyrrol-2-yl, 1H-indol-3-yl, or 2-quinolinyl, each of which is optionally substituted by one or more of the following: nitro, methyl, acetyl or chloro.
- 14. A compound selected from:
 N-(9, 10-methanoanthracen-9(10H)-ylmethyl)-N-(2-quinolinyl)-1, 2-ethanediamine;
 N-(6-methoxy-4-methyl-2-quinolinyl)-N'-(3-thienylmethyl)-1, 3-propanediamine;

- N-(9, 10-methanoanthracen-9(10H)-ylmethyl)-N'-(2-quinolinyl)-1, 3-propanediamine;
- N-(2-quinolinyl)-N'-(3-thienylmethyl)-1, 3-propanediamine;
- N-(9, 10-methanoanthracen-9(10H)-ylmethyl)-N'-(2-quinolinyl)-1, 4-cyclohexanediamine;
- N-[(1-acetyl-1H-indol-3-yl)methyl]-N'-(6-methoxy-4-methyl-2-quinolinyl)-1, 3-
- s propanediamine;
 - N-(9, 10-methanoanthracen-9(10H)-ylmethyl)- N-(2-quinolinyl)-1, 3-cyclohexanediamine;
 - N-(2-quinolinyl)-N'-[1-(3-thienyl)ethyl]-1, 3-propanediamine;
 - N-(2-quinolinyl)-N'-(3-thienylmethyl)-1, 3-cyclohexanediamine;
- N-(9,10-methanoanthracen-9(10H)-ylmethyl)-N-(6-methoxy-4-methyl-2-quinolinyl)-1, 3-propanediamine;
 - N-(2-quinolinyl)-N'-(4, 5, 6, 7-tetrahydrothianaphth-4-yl)-1, 3-propanediamine;
 - N-methyl-N'-(2-quinolinyl)-N-(3-thienylmethyl)-1, 3-propanediamine;
 - N-(2-quinolinyl)-N', N'-bis(3-thienylmethyl)-1, 3-propanediamine;
- N- (9, 10-methanoanthracen-9(10H)-ylmethyl)-N-methyl-N'-(2-quinolinyl)-1, 3-propanediamine;
 - N-(2-quinolinyl)-N'-[(2, 4, 6-trimethylphenyl)methyl]-1, 3-propanediamine;
 - N-(2-phenylethyl)-N'-(2-quinolinyl)-1, 3-propanediamine;
 - N-(1-benzo[b]thien-3-ylethyl)-N'-(2-quinolinyl)-1, 3-propanediamine;
- N-[(3, 4-dichlorophenyl)methyl]-N'-(2-quinolinyl)-1, 3-cyclohexanediamine;
 - N-(9, 10-methanoanthracen-9(10H)-ylmethyl)-N'-methyl-N'-(2-quinolinyl)-1, 3-propanediamine;
 - N-(2-quinolinyl)-N'-(2-thienylmethyl)-1, 3-propanediamine;
 - N-(3-furanylmethyl)-N'-(2-quinolinyl)-1, 3-propanediamine;
- N-[(3, 4-dichlorophenyl)methyl]-N-methyl-N'-(2-quinolinyl)-1, 3-propanediamine;
 - N-[1-(9, 10-methanoanthracen-9(10H)-ylmethyl)-4-piperidinyl]-2-quinolinamine;
 - N-(1H-indol-3-ylmethyl)-N'-(2-quinolinyl)-1, 3-propanediamine;
 - N-(2-naphthalenylmethyl)-N-(2-quinolinyl)-1, 3-propanediamine;
 - N-(2, 2-diphenylethyl)-N'-(2-quinolinyl)-1, 3-propanediamine;
- N-(1H-indol-3-ylmethyl)-N'-(6-methoxy-4-methyl-2-quinolinyl)-1, 3-propanediamine;
 - N-[(3, 4-dichlorophenyl)methyl-N'-(2-quinolinyl)-1, 3-propanediamine;
 - N-[(3, 4-dichlorophenyl)methyl]-N'-(2-quinolinyl)-1, 4-cyclohexanediamine;

- N, N'-di-(2-quinolinyl)-1, 3-propanediamine;
- N-(2-quinolinyl)-N'-(2-quinolinylmethyl)-1, 3-propanediamine;
- N-[(1-acetyl-1H-indol-3-yl)methyl]-N-(2-quinolinyl)-1, 3-propanediamine;
- N-(cyclopropylmethyl)-N'-(2-quinolinyl)-1, 3-propanediamine;
- 5 N-(2-quinolinyl)-N'-(3-thienylmethyl)-1, 4-cyclohexanediamine;
 - N-([1, 1'-biphenyl]-4-ylmethyl)-N'-(2-quinolinyl)-1, 3-propanediamine;
 - N-(6-methoxy-4-methyl-2-quinolinyl)-N'-[3-(5-methyl-2-furanyl)butyl]-1, 3-propanediamine;
 - N-[[4-(dimethylamino)phenyl]methyl]-N-(2-quinolinyl)-1, 3-propanediamine;
- N-(1H-pyrrol-2-ylmethyl)-N-(2-quinolinyl)-1, 3-propanediamine;
 - N-[3-(5-methyl-2-furanyl)butyl]-N'-(2-quinolinyl)-1, 3-propanediamine;
 - N-[(5-nitro-3-thienyl)methyl]-N'-(2-quinolinyl)-1, 3-propanediamine:
 - N-(6-methoxy-4-methyl-2-quinolinyl)-N'-[(5-nitro-3-thienyl)methyl]-1, 3-propanediamine;
 - N-(6-methoxy-4-methyl-2-quinolinyl)-N'-(1H-pyrrol-2-ylmethyl)-1, 3-propanediamine;
- N-[(3,4-dichlorophenyl)]methyl]-N'-methyl-N'-2-quinolinyl]-1, 3-propanediamine:
 - N-[1-(2,5-dimethyl-3-thienyl)ethyl]-N-(2-quinolinyl)-1,3-propanediamine;
 - N-[1-(2,5-Dichloro-thiophen-3-yl)-ethyl]-N-(2-quinolinyl)-1,3-propanediamine:
 - N-[(1-acetyl-1H-indol-3-yl)methyl]-N-quinolin-2-ylcyclohexane-1,3-diamine;
 - N-(6-methoxy-4-methylquinolin-2-yl)-N-(3-thienylmethyl)cyclopentane-1,3-diamine;N-
- (6-methoxy-4-methylquinolin-2-yl)-N'-[(1-methyl-1H-indol-3-yl)methyl]cyclopentane-1,3-diamine:
 - (15,35)-N-(6-methoxy-4-methylquinolin-2-yl)-N-[(1-methyl-1H-indol-3-
 - yl)methyl]cyclopentane-1,3-diamine
 - (15,35)-N-(6-methoxy-4-methylquinolin-2-yl)-N-(3-thienylmethyl)cyclopentane-1,3-
- 25 diamine
 - N-[(1-acetyl-1*H*-indol-3-yl)methyl]-N-(6-methoxy-4-methylquinolin-2-yl)cyclohexane-1,3-diamine;
 - N-(1H-indol-3-ylmethyl)-N-(6-methoxy-4-methylquinolin-2-yl)cyclohexane-1,3-diamine;
 - N-(6-methoxy-4-methylquinolin-2-yl)-N-(3-thienylmethyl)cyclohexane-1,3-diamine;
- N-(6-methoxy-4-methylquinolin-2-yl)-N-[(1-methyl-1H-indol-3-yl)methyl]cyclohexane-1,3-diamine;

N-(1-benzofuran-2-ylmethyl)-N'-(6-methoxy-4-methylquinolin-2-yl)cyclohexane-1,3-diamine; N-(6-methoxy-4-methylquinolin-2-yl)-N'-(pyridin-2-ylmethyl)cyclohexane-1,3-diamine_and

N-(4-methylquinolin-2-yl)-N'-(3-thienylmethyl)cyclohexane-1,3-diamine;

- s as well as pharmaceutically acceptable salts thereof.
 - 15. A compound of formula I as claimed in any previous claim for use as a medicament.
 - 16. A pharmaceutical formulation comprising a compound of formula I, as defined in any one of claims 1 to 14 and a pharmaceutically acceptable adjuvant, diluent or carrier.
 - 17. Use of a compound of formula I, as defined in any one of claims 1 to 14 in the preparation of a medicament for the treatment or prophylaxis of conditions associated with obesity.
 - 18. A method of treating obesity, psychiatric disorders, anxiety, anxio-depressive disorders, depression, bipolar disorder, ADHD, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders and pain related disorders, comprising administering a pharmacologically effective amount of a compound as claimed in any one of claims 1 to 14 to a patient in need thereof.

 19. A compound as defined in any one of claims 1 to 14 for use in the treatment of obesity.
- 20. A process for the preparation of compounds of formula I comprising reacting a compound of formula II

II

in which R^1 , R^2 , R^3 , R^4 , L^1 , n and m are as previously defined with a compound of formula III

m

in which R^5 is as previously defined and L^2 represents a group which after reaction of compounds II and III gives L^2 on reduction, under reductive alkylation conditions.

21. Intermediates of formula II

$$(R^{1})_{n} = \begin{pmatrix} \begin{pmatrix} & & \\ & & \\ & & \end{pmatrix} \begin{pmatrix} & & \\ & & \\ & & & \end{pmatrix} \begin{pmatrix} & & \\ & & & \\ & & & \\ & & & \end{pmatrix} \begin{pmatrix} & & \\ & & & \\ & & & \\ & & & \\ & & & \end{pmatrix} \begin{pmatrix} & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \end{pmatrix} \begin{pmatrix} & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \end{pmatrix} \begin{pmatrix} & & \\ & & \\ & & \\ & & \\ & & \\ & & \end{pmatrix} \begin{pmatrix} & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \end{pmatrix} \begin{pmatrix} & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \end{pmatrix} \begin{pmatrix} & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \end{pmatrix} \begin{pmatrix} & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ \end{pmatrix} \begin{pmatrix} & & \\ \end{pmatrix} \begin{pmatrix} & & & \\$$

1

in which R^1 , R^2 , R^3 , R^4 , L^1 , n and m are as defined in claim 1.

10